CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ — Merrimack
Pharmaceuticals today announced that it will present at the Stifel
Nicolaus 2010 Healthcare Conference in Boston. William Sullivan,
Vice President of Finance, will provide a company overview at
11:30am, EDT, Friday, September 17, 2010 at the Four Seasons Hotel
in Boston, Massachusetts.
(Logo:
http://photos.prnewswire.com/prnh/20100913/NE63515LOGO)
(Logo:
http://www.newscom.com/cgi-bin/prnh/20100913/NE63515LOGO)
About MerrimackMerrimack Pharmaceuticals, Inc. is a
biopharmaceutical company dedicated to the discovery and
development of novel medicines for the treatment of cancer and
inflammation. The Company is advancing a robust pipeline of
engineered therapeutics paired with molecular diagnostics.
Merrimack has three oncology candidates in clinical development:
MM-121, partnered with sanofi-aventis, in Phase 2 clinical testing,
MM-111 in Phase 1/2 clinical testing, MM-398, partnered with
PharmaEngine, Inc., in Phase 2 clinical testing and multiple
pre-clinical development and research stage programs in the
pipeline. MM-121, MM-111, and MM-398 are investigational drugs and
have not been approved by the U.S. Food and Drug Administration or
any international regulatory agency. The Company’s proprietary
Network Biology discovery platform, developed with the help of
leading scientists from MIT and Harvard, integrates the fields of
engineering, biology and computing to enable mechanism-based model
driven discovery and development of both therapeutics and
diagnostics. Merrimack is a privately-held company based in
Cambridge, Massachusetts. For additional information, please visit
http://www.merrimackpharma.com.
ContactsKathleen Petrozzelli, Corporate Communications,
617-441-1043,
kpetrozzelli@merrimackpharma.com, http://www.merrimackpharma.com
Betsy Ra
‘/>”/>
